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ABSTRACT Several composite markers have been proposed for risk assessment in chronic obstructive
pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability.
Our aim was to provide and validate a simplified COPD risk index independent of lung function.
The PROMISE study (n=530) was used to develop a novel prognostic index. Index performance was
assessed regarding 2-year COPD-related mortality and all-cause mortality. External validity was tested in
stable and exacerbated COPD patients in the ProCOLD, COCOMICS and COMIC cohorts (total n=2988).
Using a mixed clinical and statistical approach, body mass index (B), severe acute exacerbations of
COPD frequency (AE), modified Medical Research Council dyspnoea severity (D) and copeptin (C) were
identified as the most suitable simplified marker combination. 0, 1 or 2 points were assigned to each
parameter and totalled to B-AE-D or B-AE-D-C. It was observed that B-AE-D and B-AE-D-C were at
least as good as BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity), ADO (age,
dyspnoea, airflow obstruction) and DOSE (dyspnoea, obstruction, smoking, exacerbation) indices for
predicting 2-year all-cause mortality (c-statistic: 0.74, 0.77, 0.69, 0.72 and 0.63, respectively; Hosmer–
Lemeshow test all p>0.05). Both indices were COPD specific (c-statistic for predicting COPD-related 2-
year mortality: 0.87 and 0.89, respectively). External validation of B-AE-D was performed in COCOMICS
and COMIC (c-statistic for 1-year all-cause mortality: 0.68 and 0.74; c-statistic for 2-year all-cause
mortality: 0.65 and 0.67; Hosmer–Lemeshow test all p>0.05).
The B-AE-D index, plus copeptin if available, allows a simple and accurate assessment of COPD-related risk.
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Introduction
Chronic obstructive pulmonary disease (COPD), one of the leading causes of death and disability, has
become a major global epidemic throughout the world [1, 2]. Subsumed under “not fully reversible airway
obstruction” COPD is a very heterogeneous disease with numerous molecular and clinical patterns [3]. To
overcome the complexity of COPD and the limitations of lung function, a number of composite markers
were introduced to assess outcome. Several scores, including the BODE index (body mass index (BMI),
airflow obstruction, dyspnoea, exercise capacity), ADO index (age, dyspnoea, airflow obstruction) and
DOSE index (dyspnoea, obstruction, smoking, exacerbation) predict COPD-related outcomes better than
airflow obstruction alone [4–6]. However, several features of the index parameters are difficult to assess
and may restrict routine clinical application. Exercise tests, as well as lung function tests, are associated
with a certain test effort and rely on patient motivation. Parameters such as age and most comorbidities
cannot be improved and thus do not qualify for serial assessment [7]. Scores incorporating lung function
parameters do not allow risk stratification during an acute exacerbation of COPD (AECOPD). However,
many patients might not present for follow-up or may exacerbate repeatedly before assessment of stable
disease. Perhaps most importantly, simple tools such as the CURB-65 (confusion, urea 7 mmol·L−1,
respiratory rate ⩾30 breaths·min−1, blood pressure <90 mmHg (systolic), ⩽60 mmHg (diastolic), age
⩾65 years) are frequently used for risk stratification in pneumonia [8], but many clinicians are very
reluctant to use more complicated scores. Novel indices of COPD-related risk, especially if including
markers of stress and inflammation, might qualify for simplified risk assessment.
The aim of this study was to provide a novel simplified COPD-specific risk index for clinical application in
stable and exacerbated disease and to assess whether excluding lung function parameters limits risk prediction.
Methods
Study design and patients
The investigator-driven PROMISE (Predicting Outcome using Systemic Markers in Severe Exacerbations of
Chronic Obstructive Pulmonary Disease; www.isrctn.com ISRCTN99586989) cohort study was employed
for the development of a novel risk index. PROMISE was a multi-centre longitudinal COPD study
performed at 11 European tertiary respiratory centres evaluating predictors of outcome in COPD, during
stable and exacerbated disease [9, 10]. Stable COPD patients in Global Initiative for Chronic Obstructive
Lung Disease (GOLD) grade II–IV were included. Index validation was performed in the ProCOLD,
COCOMICS and COMIC cohorts. ProCOLD (Procalcitonin guided-antibiotic therapy in acute
exacerbations of Chronic Obstructive Lung Disease) was a single centre COPD trial including hospitalised
patients with COPD exacerbation [11]. Patients were required to meet the definition of severe AECOPD
and spirometric COPD criteria. COCOMICS (Collaborative Cohorts to Assess Multicomponent Indices of
COPD in Spain) includes individual patient data of several COPD cohorts in Spain [12]. Seven
COCOMICS cohorts including stable COPD patients (Requena [13], Sevilla [14], Tenerife [15], Zaragoza
[16]) and exacerbated COPD patients (Terrassa I–III [17, 18]) were used for index validation. COMIC
(Cohort of Mortality and Inflammation in COPD) was a single centre study including stable and
exacerbated COPD patients from the Netherlands [19]. All studies were approved by the local institutional
review boards and all patients gave written informed consent. Detailed study characteristics are described
in the supplementary material.
Predictors
Medical history, including the number of AECOPD and severe AECOPD within the previous year, clinical
assessment and other predictors of outcome were evaluated at baseline (study inclusion). Lung function
tests, 6-min walk distance and the modified Medical Research Council (mMRC) questionnaire were
performed as described previously [20–23]. Serum copeptin levels were assessed in PROMISE and
ProCOLD. AECOPD was defined as an acute sustained worsening of dyspnoea, cough and/or sputum
beyond normal day-to-day variations in a patient with underlying COPD; a severe AECOPD was defined
as a COPD exacerbation requiring hospitalisation [24, 25]. If a cause other than COPD was dominant, as
assessed by the attending physician, the deterioration was not regarded as an AECOPD. In the
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COCOMICS cohorts a severe AECOPD was defined as an exacerbation requiring an emergency room visit
or hospitalisation. In PROMISE, the 1-year study assessment was used for internal validation. The already
established indices BODE, updated BODE (a recalibrated BODE index), ADO and DOSE were calculated
as reported previously [4–6].
Outcome
The main outcome was all-cause mortality. In PROMISE, survival was assessed during the 2-year study
follow-up. For every death, a physician defined the cause of death as COPD related, COPD unrelated or
unknown. A subset of PROMISE patients (all patients included in the study centre in Basel, Switzerland)
was additionally contacted 5 years after study inclusion to assess the survival status. Follow-up of the index
development and validation cohorts are outlined in figures E1 and E2.
Variable selection
Index variables were selected using a clinical and statistical approach. All parameters had to fulfil four
criteria. 1) COPD specificity: parameters were required to be reasonably related to COPD; 2) modifiability:
to capture deterioration and improvement during the disease course parameters were required to be
modifiable; 3) applicability: to facilitate clinical use parameters had to be easily applicable; 4) to predict
outcome independently. Parameters such as age and comorbidities did not qualify due to the missing
COPD specificity and non-modifiability. The 6-min walk distance, the lung function test and the
St George’s Respiratory Questionnaire did not qualify due to limitations in applicability, especially during
exacerbations. The performance for predicting outcome was evaluated using univariate and multivariate cox
regression analysis (tables E1 and E2). Smoking status and the number of total (moderate plus severe)
exacerbations were excluded due to poor performance. BMI, the number of severe AECOPD, mMRC and
copeptin remained the clinically most suitable and well-performing parameters. Furthermore, an entirely
statistical approach was used to identify the best predictors for 2-year all-cause-mortality out of 58
parameters [26]. 10 parameters were selected including BMI, the number of severe AECOPDs, mMRC and
copeptin (data not shown). In a second approach several other predictors were added to the model to test
its performance (table E3). When age, sex, forced expiratory volume in 1 s (FEV1), smoking status or 6-min
walk distance were added to these parameters the c-statistic of the regression models for predicting 2-year
all-cause mortality improved by <0.01, providing only minor additional predictive performance.
Development of simplified and optimised indices
The four parameters BMI (B), severe AECOPD frequency (AE), mMRC dyspnoea severity (D) and
copeptin (C) qualified for the novel risk index. Each parameter was stratified into three risk groups. The
allocation was largely based on established cut-offs (tables 1 and 2). In two simplified scores (simplified
B-AE-D and simplified B-AE-D-C) 0, 1 or 2 points were assigned to each risk group (table 1). Cox
proportional hazard survival analysis was used to develop two optimised scores (optimised B-AE-D and
optimised B-AE-D-C), with an individual number of points assigned (table 2 and table E4). An increasing
number of points indicate an increased risk.
Statistics
Discrete variables are expressed as counts (%) and continuous variables as mean±SD. Within group analyses
of copeptin levels in survivors and nonsurvivors at baseline and at specified months before death were
assessed by the Wilcoxon signed-rank test. Cox regression models were applied for index development,
point allocation in optimised indices, assessment of index performance and validation. Performance of
predictive models can be assessed by measures of discrimination and calibration. While discrimination
describes the discriminative ability, calibration refers to the agreement of observed and predicted outcomes
[27]. The c-statistic was used as a measure of discrimination and the Hosmer–Lemeshow goodness-of-fit
TABLE 1 Assignment of points for the simplified B-AE-D and B-AE-D-C index
0 points 1 point 2 points
B BMI kg·m−2 ⩾21 <21 <18.5
AE Number of severe AECOPD the previous year 0 1 ⩾2
D mMRC dyspnoea score (at stable disease) 0–2 3 4
C Copeptin at inclusion pmol·L−1 <20 ⩾20 ⩾40
BMI: body mass index; AECOPD: acute exacerbations of chronic obstructive pulmonary disease; mMRC:
modified Medical Research Council.
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test was applied for calibration. The latter evaluates whether predicted and observed risk differ across
separate risk groups. Time to death was described by Kaplan–Meier survival curves and analysed by the log
rank test. All tests were two-tailed and a p-value <0.05 was defined as significant. Data were analysed using
SPSS version 20 (IBM, Armonk, NY, USA) and R project (www.r-project.org).
Results
530 patients from the PROMISE population with a mean±sd age of 67±10 years, who were predominantly
male (70%) and with a mean±SD FEV1 of 49±17% pred were included (figure E1). Baseline characteristics
are summarised in table E5. Patients with a follow-up of at least 2 years were more likely to have
pulmonary hypertension, previous lung volume reduction surgery and pulmonary rehabilitation (p=0.047,
0.017 and 0.026, respectively). In contrast, patients excluded or lost to follow-up were more likely to
smoke, had a higher number of previous exacerbations and required more long-term oxygen therapy
(p=0.022, 0.001 and 0.047, respectively). All other baseline characteristics were similar between both
groups. The 2-year all-cause mortality was 12% (n=54). The cause of death within 2 years was
COPD-related in 46% (n=25), COPD was unrelated in 37% (n=20) and unknown in 17% (n=9). In 231
out of 233 patients from the study centre in Basel a 5-year follow-up was available. The 5-year all-cause
mortality was 36% (n=82).
Individual parameters for predicting 2-year all-cause mortality
To assess individual parameters for predicting 2-year all-cause mortality, univariate Cox regression models
were performed (table E1). Next to age, the BODE parameters (BMI, FEV1 % pred, mMRC and 6 min
walking distance), the number of severe AECOPD, the St George’s Respiratory Questionnaire and copeptin
predicted 2-year all-cause mortality (all p<0.01). Interestingly, the performance of the GOLD combined
TABLE 2 Assignment of points for the optimised B-AE-D and B-AE-D-C index
0 points 3 points 6 points 7 points 9 points 10 points
B BMI kg·m−2 ⩾21 <21 <18.5
AE Number of severe AECOPD the previous year 0 1 ⩾2
D mMRC dyspnoea score (at stable disease) 0–2 3 4
C Copeptin at inclusion pmol·L−1 <20 ⩾20 ⩾40
BMI: body mass index; AECOPD: acute exacerbations of chronic obstructive pulmonary disease; mMRC: modified Medical Research Council.
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FIGURE 1 Distribution of copeptin levels a) in 2-year survivors and nonsurvivors at baseline and b) at specified
time-points before death. Within group analyses were performed using Wilcoxon’s signed rank test.
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assessment groups (A, B, C, D) and the total number of moderate and severe AECOPD in predicting
outcome was poor (p=0.076 and 0.055, respectively).
Multivariate Cox regression models were performed to identify independent predictors of all-cause
mortality (table E2). FEV1 was not an independent predictor in any score. In contrast, mMRC
independently predicted death within all indices. Copeptin was an independent predictor of 2-year
all-cause mortality in all investigated models (also when added to parameters of BODE, updated BODE,
ADO and DOSE; p⩽0.001 in all). Copeptin levels were not different between stable or exacerbated COPD
(stable disease versus moderate exacerbation (n=100): mean copeptin difference 1.8±12.5 pmol·L−1, p=0.2;
stable disease versus severe exacerbation (n=41): mean copeptin difference 10.7±40.9 pmol·L−1, p=0.10).
Interestingly, copeptin levels were highest within 6 months prior to death (figure 1).
Index performance in predicting all-cause mortality
The score performance was assessed using the c-statistic (discrimination) and Hosmer–Lemeshow
goodness-of-fit test (calibration). The point assignments of the simplified and optimised B-AE-D and
B-AE-D-C indices are described in tables 1 and 2. Among the established indices, the BODE and updated
BODE score discriminated best in predicting 1-year all-cause mortality (table 3). In the subgroup of
TABLE 3 Discrimination and calibration for predicting all-cause mortality in the PROMISE study
Indices 1-year mortality# 2-year mortality¶
C-statistic (95% CI) Calibration C-statistic (95% CI) Calibration
BODE index+ 0.76 (0.65–0.87) 0.9 0.69 (0.61–0.78) 0.2
Updated BODE index+ 0.78 (0.67–0.89) 0.7 0.70 (0.61–0.78) 0.6
ADO index§ 0.72 (0.62–0.82) 0.3 0.72 (0.64–0.79) 0.8
DOSE index§ 0.64 (0.54–0.73) 0.9 0.63 (0.55–0.70) 0.8
Simplified B-AE-D index 0.78 (0.68–0.87) 0.4 0.74 (0.67–0.81) 0.5
Simplified B-AE-D-C index 0.80 (0.71–0.90) 0.7 0.77 (0.70–0.85) 0.9
Optimised B-AE-D index 0.78 (0.69–0.88) 0.9 0.75 (0.68–0.82) 0.9
Optimised B-AE-D-C index 0.81 (0.71–0.91) 0.2 0.78 (0.70–0.85) 0.2
PROMISE: Predicting Outcome using Systemic Markers in Severe Exacerbations of Chronic Obstructive
Pulmonary Disease; BODE: body mass index, airflow obstruction, dyspnoea, exercise capacity; ADO: age,
dyspnoea, airflow obstruction; DOSE: dyspnoea, obstruction, smoking, exacerbation; B: body mass index;
AE: severe acute exacerbation of chronic obstructive pulmonary disease frequency; D: modified Medical
Research Council dyspnoea severity; C: copeptin. #: n=530; ¶: n=460; +: missing values in lung function test
or 6-min walking distance (1 year: n=488, 2 years: n=416); §: missing values in lung function test (1 year:
n=525, 2 years: n=444).
TABLE 4 Discrimination and calibration for predicting all-cause mortality in the 5-year
follow-up subpopulation of the PROMISE study
Indices 3-year mortality 5-year mortality#
C-statistic (95% CI) Calibration C-statistic (95% CI) Calibration
BODE index¶ 0.59 (0.50–0.67) 0.6 0.60 (0.54–0.67) 0.6
Updated BODE index¶ 0.60 (0.52–0.69) 0.9 0.62 (0.55–0.68) 0.4
ADO index+ 0.67 (0.59–0.75) 0.11 0.68 (0.61–0.74) 0.2
DOSE index+ 0.58 (0.50–0.65) 0.7 0.58 (0.52–0.64) 0.2
Simplified B-AE-D index 0.65 (0.57–0.72) 0.2 0.62 (0.57–0.67) 0.3
Simplified B-AE-D-C index 0.71 (0.64–0.79) 0.7 0.68 (0.62–0.74) 0.4
Optimised B-AE-D index 0.65 (0.57–0.72) 0.3 0.62 (0.56–0.68) 0.2
Optimised B-AE-D-C index 0.71 (0.63–0.78) 0.10 0.67 (0.61–0.73) 0.07
PROMISE: Predicting Outcome using Systemic Markers in Severe Exacerbations of Chronic Obstructive
Pulmonary Disease; BODE: body mass index, airflow obstruction, dyspnoea, exercise capacity; ADO: age,
dyspnoea, airflow obstruction; DOSE: dyspnoea, obstruction, smoking, exacerbation; B: body mass index;
AE: severe acute exacerbation of chronic obstructive pulmonary disease frequency; D: modified Medical
Research Council dyspnoea severity; C: copeptin. #: n=231; ¶: 211 missing values in lung function test or
6-min walking distance; +: 229 missing values in lung function test.
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patients with 5 year follow-up the best predictor for 3- and 5-year all-cause mortality was the ADO index
(table 4). BODE and ADO were the best predictors of 2-year all-cause mortality. Discrimination declined
for predicting 3- and 5-year all-cause mortality. Simplified and optimised B-AE-D and B-AE-D-C indices
performed at least as good as other indices in predicting all-cause mortality up to 5 years. Lung function
parameters did not improve the performance of B-AE-D or B-AE-D-C in predicting 2-year all-cause
mortality (table E3). Calibration was acceptable within all scores (p>0.05). Increasing index points were
associated with worse outcome (all indices: log rank p<0.001) (figure 2).
Index performance in predicting COPD-related mortality
To assess whether indices predict COPD-related outcome (COPD-related mortality versus all other
outcomes) Cox regression models were used (table 5). Analogous analyses were performed for 2-year
COPD-unrelated mortality. B-AE-D and B-AE-D-C performed better in predicting COPD-related
mortality than established indices. ADO and B-AE-D-C were the only indices predicting COPD-unrelated
survival. Age and the adjusted Charlson comorbidity index were used for control. The performance of
both was not better in predicting COPD-related mortality compared to COPD-unrelated mortality.
Internal validation
For internal validation we used all B-AE-D-C parameters 1 year after study inclusion during stable disease
rather than a statistical approach. Points were assigned as described above. The score performance
regarding 1-year and 4-year outcome was evaluated (n=299 and 185, respectively). Simplified B-AE-D
predicted 1- and 4-year all-cause mortality (c-statistic (95% CI) 0.74 (0.63–0.86) and 0.62 (0.54–0.69);
Hosmer–Lemeshow test: p=0.7 and 0.3, respectively). When copeptin was included (B-AE-D-C) a
performance improvement was observed for predicting 4-year all-cause mortality (c-statistic for 1- and
4-year all-cause mortality: 0.75 (0.62–0.88) and 0.68 (0.61–0.76); Hosmer-Lemeshow test: p=0.2 and 0.9,
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FIGURE 2 Kaplan-Meier estimates of the 2-year survival of simplified and optimised B-AE-D and B-AE-D-C
indices. B: body mass index; AE: severe acute exacerbation of chronic obstructive pulmonary disease
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respectively). Since optimised indices only provided a minor performance improvement at the cost of
simplicity we did not validate them.
External validation of B-AE-D-C
Score performance was validated in a different cohort of 160 patients hospitalised for AECOPD, ProCOLD
(figure E2). Patients had a mean±SD age of 71±10 years, were mainly male (56%) and had a mean±SD FEV1
of 41±18% pred (table E6). 2-year all-cause mortality was 23% (n=36). Dyspnoea severity (mMRC) was not
assessed and therefore not available. Simplified B-AE as well as simplified B-AE-C predicted 2- and 5-year
all-cause mortality (2-year all-cause mortality: c-statistic 0.60 (0.52–0.69) and 0.69 (0.60–0.78), respectively;
Hosmer–Lemeshow test: p=0.17 and 0.8, respectively; 5-year all-cause mortality: c-statistic 0.59 (0.52–0.66)
and 0.65 (0.57–0.72); Hosmer–Lemeshow test: p=0.08 and 0.2, respectively).
External validation of B-AE-D
The B-AE-D index was validated in the COCOMICS cohorts from Spain and the COMIC study from the
Netherlands. 2153 patients from seven COCOMICS cohorts were included for B-AE-D validation
(figure E2). Patients had a mean±SD age of 66±10 years, were mostly male (93%) and had a mean FEV1 of
52±20% pred (table E6). 2-year all-cause mortality was 15% (n=307). B-AE-D predicted 1-, 2- and 3-year
all-cause mortality (c-statistic: 0.68 (0.63–0.72), 0.65 (0.62–0.69) and 0.63 (0.61–0.66), respectively)
(table E7). B-AE-D was well calibrated (Hosmer–Lemeshow test: p=0.5, 0.3 and 0.2, respectively).
675 patients of the COMIC study were analysed for further B-AE-D validation (figure E2). Patients of
COMIC had a mean±SD age of 67±10 years, were predominately male (60%) and had a mean±SD FEV1 of
53±19% pred (table E6). 2-year all-cause mortality was 12% (n=82). B-AE-D at stable disease predicted 1-,
2- and 3-year all-cause mortality (c-statistic: 0.74 (0.65–0.83), 0.67 (0.61–0.72) and 0.66 (0.61–0.70),
respectively). B-AE-D was well calibrated for predicting all-cause mortality (Hosmer–Lemeshow test: p=0.2,
0.5 and 0.5, respectively).
Discussion
Herein, we propose a novel, simple and lung function independent tool for risk assessment in COPD. The
B-AE-D and B-AE-D-C indices perform as well as established more complicated indices for predicting
outcome. Both indices are COPD specific and predict death in stable and exacerbated COPD.
Clinical applicability and significance of included parameters were our priority in index generation. Thus,
parameters were primarily selected on clinical features rather than statistical performance. The BMI, severe
AECOPD frequency, dyspnoea severity and copeptin were identified as a combination of easy applicable,
predictive and relevant COPD parameters. The relevance and predictive properties of all four individual
parameters have been reported previously.
Whereas overweight appears to be protective, low body weight is a well-known predictor of mortality [28–30].
Notably, weight change is associated with a change in outcome [31, 32]. Besides the well-established
TABLE 5 Discrimination for predicting 2-year cause-specific chronic obstructive pulmonary
disease (COPD)-related and -unrelated mortality in the PROMISE study#
Indices COPD-related 2-year mortality COPD-unrelated 2-year mortality
BODE index¶ 0.86 (0.72–0.99) 0.55 (0.42–0.68)
Updated BODE index¶ 0.82 (0.68–0.96) 0.57 (0.44–0.71)
ADO index+ 0.84 (0.73–0.95) 0.65 (0.52–0.77)
DOSE index+ 0.78 (0.67–0.89) 0.52 (0.39–0.64)
Simplified B-AE-D index 0.87 (0.77–0.98) 0.60 (0.48–0.72)
Simplified B-AE-D-C index 0.89 (0.78–0.99) 0.64 (0.52–0.76)
Optimised B-AE-D index 0.88 (0.78–0.99) 0.61 (0.49–0.73)
Optimised B-AE-D-C index 0.90 (0.79–0.99) 0.65 (0.52–0.77)
Age years 0.59 (0.47–0.70) 0.64 (0.52–0.77)
Adjusted Charlson comorbidity index 0.62 (0.50–0.73) 0.62 (0.50–0.74)
Data are presented as C-statistic (95% CI). PROMISE: Predicting Outcome using Systemic Markers in Severe
Exacerbations of Chronic Obstructive Pulmonary Disease; BODE: body mass index, airflow obstruction,
dyspnoea, exercise capacity; ADO: age, dyspnoea, airflow obstruction; DOSE: dyspnoea, obstruction,
smoking, exacerbation; B: body mass index; AE: severe acute exacerbation of chronic obstructive pulmonary
disease frequency; D: modified Medical Research Council dyspnoea severity; C: copeptin.#: n=460; ¶: 416
missing values in lung function test or 6-min walking distance; +: 444 missing values in lung function test.
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threshold of BMI in COPD (21 kg·m−2) we identified a further increased risk in patients with a BMI
<18.5 kg·m−2, the established cut-off for low weight in the normal population [4, 33]. Low in-hospital
mortality and high long-term mortality is a familiar phenomenon of severe AECOPD [34]. Several studies
reported high 2-year mortality after AECOPD hospitalisation, ranging up to 49% [13, 17, 34, 35].
Interestingly, moderate AECOPD and COPD combined assessment groups, defined by frequent
exacerbations only (GOLD C2), were not associated with worse outcome, emphasising exacerbation
severity for predicting outcome [13, 36, 37]. This is in line with our finding that the total AECOPD
frequency did not predict mortality, whereas severe AECOPD predicted an unfavourable outcome. In the
majority of COPD patients, dyspnoea is the predominant and most distressing symptom associated with
poor survival not reflected by other parameters [38, 39]. Recently, it was reported that COPD GOLD B
patients have a worse survival than group C patients, despite group C patients having a poorer lung
function and/or more AECOPD [40]. Consequently, dyspnoea seems to be more relevant than lung
function and AECOPD frequency in predicting risk. However, dyspnoea may fluctuate, especially during
exacerbations, potentially affecting predictive performance unfavourably. AECOPD frequency and
dyspnoea were recently included in the GOLD recommended COPD grading system, further highlighting
the importance of both parameters. In contrast to previous COPD risk scores we did not include FEV1 in
the novel indices. This was due to the transient reduction of lung volumes during and after AECOPD and
the difficulties in performing reliable lung function measurements at exacerbation [41]. Importantly,
B-AE-D and B-AE-D-C performed as well as other indices, including airflow obstruction, and there was
no further index improvement after the addition of FEV1. Still, lung function is fundamental for COPD
diagnosis. However, once a diagnosis is established, practical and intrinsic difficulties of spirometry limit
its usefulness for risk prediction, particularly in severe COPD.
Multiple receptors throughout the body sense information and facilitate, if required, subsequent
compensatory changes by the autonomic nervous and endocrine system, among others. These well
performing systems can be employed for clinical purposes. By this means hypoxaemia, hypercapnia,
inflammation and several other stressors cause an increase in arginine vasopressin (AVP) synthesis and
release; thus, indicating AVP as a plausible COPD marker [42–44]. However, the short half-life of AVP
precludes its clinical application. Copeptin, a glycopeptide comprising the C-terminal part of the AVP
prohormone, is a stable, more reliable alternative for AVP measurement [22]. The performance of copeptin
in predicting mortality was reported previously and a threshold of 40 pmol·L−1 was suggested [45]. Herein
we demonstrate that: 1) copeptin levels are similar in stable and exacerbated COPD; 2) copeptin levels
increase within the months before death; and 3) copeptin is an independent well-performing predictor of
mortality; all of which are important features of a prognostic marker.
For index point allocation we proposed simplified and optimised indices. However, the performance in
predicting outcome was similar. Due to the main objective of simplicity, we propose the simplified
B-AE-D index for COPD risk assessment plus copeptin if available. The performance of B-AE-D-C,
including copeptin, was similar to B-AE-D for predicting 1- and 2-year all-cause mortality. However, there
was a moderate performance improvement after 2 years. Importantly, the additional value of copeptin
needs to be better defined in future investigations. Moreover, it is necessary to evaluate whether the
performance improvement justifies the additional costs.
The indices are composed of three to four parameters with three easy memorable risk groups. A 0-1-2
allocation is probably the simplest index for risk assessment in COPD to date. Although simplicity was not
at the cost of index performance as validated internally and externally. External validation of B-AE-D was
performed in the COMICS and COCOMICS cohorts. The large number of patients and variability in
COPD severity, phenotypes, and ethnical and social background allowed validation in a broad spectrum of
COPD. B-AE-D-C was validated 1 year after inclusion in PROMISE (internal validation) and in ProCOLD
without dyspnoea (external validation). Population heterogeneity within and across different cohorts
caused variation in index performance but also ensured optimal B-AE-D validation.
We also demonstrate that B-AE-D and B-AE-D-C predicted COPD-related mortality. Accordingly, the
main determinant of low BMI, severe AECOPD, dyspnoea severity and high copeptin levels is the baseline
severity of COPD; i.e. the greater the severity of COPD the greater the likeliness of low BMI, severe
AECOPD, severe dyspnoea, high copeptin and also death.
Comorbidities are common in COPD and have important therapeutic and prognostic implications [46, 47].
Moreover comorbidities, in particular cardiac disease, may increase the number of severe AECOPDs and
bias dyspnoea assessment. In line with previous findings several comorbidities had an effect on AECOPD
frequency and outcome. But importantly, comorbidities did not restrict the performance of B-AE-D or
B-AE-D-C in predicting outcome (data not shown). Furthermore, phenotypes might affect index
performance. In a previous study BODE and ADO were only poorly associated with COPD phenotypes [48].
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In PROMISE, several markers reflecting COPD phenotypes (more than two COPD exacerbations per year,
chronic cough, oxygen saturation at rest and during exercise) had no effect on B-AE-D performance (data
not shown).
We acknowledge several limitations. First, we stratified dyspnoea by using the mMRC dyspnoea scale.
Despite its frequent use and reasonably good validation, more precise tools for dyspnoea assessment are
available and may further improve predictive performance [6, 49]. Secondly, dyspnoea was not assessed in
the ProCOLD validation cohort; consequently, B-AE-C was evaluated rather than B-AE-D-C. Dyspnoea
may further increase the predictive performance of B-AE-C, however, this cannot be proved. Thirdly, due
to different inclusion criteria and study locations, patient characteristics across the cohorts are diverse and
index performance is variable; although population heterogeneity may reflect real-life conditions. Finally,
ethnicity and differences in dyspnoea perception possibly affect B-AE-D point allocation and potentially
performance. Thus, further validation across a range of disease severities and different populations outside
Europe is required.
However, a large sample size with a sufficient number of events, follow-up time of 5 years, assessment of
both all-cause and COPD-related mortality, as well as internal and extensive external validation are
strengths of the current study, mostly not provided in reports of other novel COPD indices. This study
allowed us to establish a very simple lung function independent index of risk in COPD. B-AE-D is easy to
obtain, COPD-specific and performs at stable and exacerbated COPD. Furthermore, B-AE-D is assessed at
almost no cost, therefore, accessible in high- and low-income countries.
To conclude, the B-AE-D index, plus copeptin where available, allows a simple and accurate assessment of
COPD-related risk in the absence of lung function.
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